Drug Profile
Cytomegalovirus immune globulin - Cangene
Latest Information Update: 11 Oct 2002
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 11 Oct 2002 Discontinued - Preclinical for Cytomegalovirus infections in Canada (unspecified route)
- 21 Jun 2001 Cangene still considers CMV a potential hyperimmune target
- 21 Jun 2001 No-Development-Reported for Cytomegalovirus infections in Canada (Unknown route)